Professor Michael S. Hofman
Professor Michael S. Hofman
Consultant Physician, Peter MacCallum Cancer Centre & University of Melbourne
Verified email at
TitleCited byYear
Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and …
M Perera, N Papa, D Christidis, D Wetherell, MS Hofman, DG Murphy, ...
European urology 70 (6), 926-937, 2016
International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers
A Biggi, A Gallamini, S Chauvie, M Hutchings, L Kostakoglu, M Gregianin, ...
Journal of Nuclear Medicine 54 (5), 683-690, 2013
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
A Gallamini, SF Barrington, A Biggi, S Chauvie, L Kostakoglu, ...
Haematologica 99 (6), 1107-1113, 2014
High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours
MS Hofman, G Kong, OC Neels, P Eu, E Hong, RJ Hicks
Journal of medical imaging and radiation oncology 56 (1), 40-47, 2012
Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation
MS Hofman, WFE Lau, RJ Hicks
Radiographics 35 (2), 500-516, 2015
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ...
The Lancet Oncology 19 (6), 825-833, 2018
Is there still a role for SPECT–CT in oncology in the PET–CT era?
RJ Hicks, MS Hofman
Nature reviews Clinical oncology 9 (12), 712, 2012
Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
JM Beauregard, MS Hofman, JM Pereira, P Eu, RJ Hicks
Cancer Imaging 11 (1), 56, 2011
Prostate-specific membrane antigen ligands for imaging and therapy
M Eiber, WP Fendler, SP Rowe, J Calais, MS Hofman, T Maurer, ...
J Nucl Med 58 (Suppl 2), 67S-76S, 2017
Validating and improving CT ventilation imaging by correlating with ventilation 4D‐PET/CT using 68Ga‐labeled nanoparticles
J Kipritidis, S Siva, MS Hofman, J Callahan, RJ Hicks, PJ Keall
Medical physics 41 (1), 011910, 2014
The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
JM Beauregard, MS Hofman, G Kong, RJ Hicks
European journal of nuclear medicine and molecular imaging 39 (1), 50-56, 2012
68Ga PET/CT ventilation–perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy
MS Hofman, JM Beauregard, TW Barber, OC Neels, P Eu, RJ Hicks
Journal of Nuclear Medicine 52 (10), 1513-1519, 2011
Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT
RJ Clifton-Bligh, MS Hofman, E Duncan, IW Sim, D Darnell, A Clarkson, ...
The Journal of Clinical Endocrinology & Metabolism 98 (2), 687-694, 2013
Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy
CY Cheah, MS Hofman, M Dickinson, A Wirth, D Westerman, SJ Harrison, ...
British journal of cancer 109 (2), 312, 2013
Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients
E Quak, PY Le Roux, MS Hofman, P Robin, D Bourhis, J Callahan, ...
European journal of nuclear medicine and molecular imaging 42 (13), 2072-2082, 2015
Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls
MS Hofman, RJ Hicks, T Maurer, M Eiber
Radiographics 38 (1), 200-217, 2017
68 Ga-DOTATATE and 18 F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity
CA Chang, DA Pattison, RW Tothill, G Kong, TJ Akhurst, RJ Hicks, ...
Cancer Imaging 16 (1), 22, 2016
Changing paradigms with molecular imaging of neuroendocrine tumors
MS Hofman, RJ Hicks
Discovery medicine 14 (74), 71-81, 2012
Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours
R Kashyap, MS Hofman, M Michael, G Kong, T Akhurst, P Eu, D Zannino, ...
European journal of nuclear medicine and molecular imaging 42 (2), 176-185, 2015
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
G Kong, M Thompson, M Collins, A Herschtal, MS Hofman, V Johnston, ...
European journal of nuclear medicine and molecular imaging 41 (10), 1831-1844, 2014
The system can't perform the operation now. Try again later.
Articles 1–20